Overview

Sabai Global has been acquired by Thompson Street Capital Partners to accelerate IBC and IRB growth.

Significance

Cell and gene therapies (C&GT) are one of the fastest-growing areas of therapeutics, contributing to some of the most significant disruptions in the pharmaceutical and biotech industries. In a fast-paced market expected to exceed $42 billion by 2030, sponsors and CROs rely on specialized Institutional Biosafety Committees (IBCs) and Institutional Review Boards (IRBs) to address the unique biosafety challenges presented by C&GT clinical trials.

Sabai Global (Sabai) provides IBC, IRB, and related consulting services through its three operating subsidiaries: Clinical Biosafety Services (CBS); Castle IRB (Castle); and Shield Consulting (Shield). CBS provides accelerated, compliant review of gene transfer/gene therapy clinical trials to a convened review of a site-specific Institutional Biosafety Committee (IBC). Castle offers IRB review services in many areas of research, including cell and gene therapy, and rare disease space. Shield provides expert consulting services on issues of biosafety, biorisk management and biosecurity. The combined value of these specialized services made Sabai the ideal target for a strategic growth investment from Thompson Street Capital Partners.

Crosstree’s Role

Crosstree acted as exclusive financial advisor to Sabai Global in its acquisition by Thompson Street through:

• Leveraging market expertise to create a strong value proposition that connected client capabilities with market trends
• Developing and articulating a compelling narrative for potential buyers
• Evaluating a broad slate of potential financial partners to help the founder implement his vision for continued growth